Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression.J Pharmacol Exp Therapeut. 2011; 336: 496-505
- Metformin inhibits prostate cancer progression by targeting tumor-associated inflammatory infiltration.Clin Cancer Res. 2018; 24: 5622-5634
- Effects of metformin and statins on outcomes in men with castrate resistant metastatic prostate cancer: secondary analysis of COU-AA-301 and COU-AA-302.Eur J Canc. 2022; 170: 296-304
- Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: a meta-analysis of AFFIRM, PREVAIL and PROSPER.Eur J Canc. 2022; 170: 285-295
- Influence of enzalutamide on cabazitaxel pharmacokinetics: a drug-drug interaction study in metastatic castration-resistant prostate cancer (mCRPC) patients.Clin Cancer Res. 2018; 24: 541-546
- Drug-drug interaction potential of darolutamide: in vitro and clinical studies.Eur J Drug Metab Pharmacokinet. 2019; 44: 747-759
- Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.Clin Cancer Res. 2012; 18: 4433-4440
- Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer.Br J Cancer. 2020; 123: 1715-1719
- Environmental and genetic factors affecting transport of imatinib by OATP1A2.Clin Pharmacol Ther. 2011; 89: 816-820
- Drug transporters of platinum-based anticancer agents and their clinical significance.Drug Resist Updates. 2011; 14: 22-34